BIOMAT Database Logo BIOMAT Database Logo

Influence of L-glutamic acid on binding of interleukin-1beta, tumour necrosis factor-alpha and interleukin-6 to HL-60 cells. 1998

I A Kostanyan, and R I Nurieva, and E V Navolotskaya, and M V Astapova, and S M Dranitsina, and A P Bogachuk, and V P Zav'yalov, and V M Lipkin
Shemyakin-Ovchinnikov Institute of Bio-organic Chemistry, Russian Academy of Sciences, Moscow.

To elucidate the mechanism of differentiating activity on L-Glu to HL-60 cells, its influence on binding of human recombinant interleukine-1beta (rHuIL-1beta), tumour necrosis factor-alpha (rHuTNF-alpha) and interleukine-6 (IL-6) by HL-60 cells was studied. It was established, that L-Glu converted the high affinity binding of [125I]rHuIL-1beta (Kd = 0.32 nM) and [125I]rHuIL-6 (Kd = 0.075 nM) to HL-60 cells into low affinity (corresponding Kd values -13.3 and 2.1 nM) at concentration 0.1 microM. The preincubation for an hour of HL-60 cells with 0.1 microM L-Glu was shown to result in an increase of affinity and number of [125I]rHuTNF-alpha binding sites. Thus, L-Glu decreases the sensitivity of the HL-60 cells to IL-1beta and IL-6 and increases TNF-alpha binding at concentration 0.1 microM.

UI MeSH Term Description Entries
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D007553 Isotope Labeling Techniques for labeling a substance with a stable or radioactive isotope. It is not used for articles involving labeled substances unless the methods of labeling are substantively discussed. Tracers that may be labeled include chemical substances, cells, or microorganisms. Isotope Labeling, Stable,Isotope-Coded Affinity Tagging,Isotopically-Coded Affinity Tagging,Affinity Tagging, Isotope-Coded,Affinity Tagging, Isotopically-Coded,Isotope Coded Affinity Tagging,Labeling, Isotope,Labeling, Stable Isotope,Stable Isotope Labeling,Tagging, Isotope-Coded Affinity,Tagging, Isotopically-Coded Affinity
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D015850 Interleukin-6 A cytokine that stimulates the growth and differentiation of B-LYMPHOCYTES and is also a growth factor for HYBRIDOMAS and plasmacytomas. It is produced by many different cells including T-LYMPHOCYTES; MONOCYTES; and FIBROBLASTS. Hepatocyte-Stimulating Factor,Hybridoma Growth Factor,IL-6,MGI-2,Myeloid Differentiation-Inducing Protein,Plasmacytoma Growth Factor,B Cell Stimulatory Factor-2,B-Cell Differentiation Factor,B-Cell Differentiation Factor-2,B-Cell Stimulatory Factor 2,B-Cell Stimulatory Factor-2,BSF-2,Differentiation Factor, B-Cell,Differentiation Factor-2, B-Cell,IFN-beta 2,IL6,Interferon beta-2,B Cell Differentiation Factor,B Cell Differentiation Factor 2,B Cell Stimulatory Factor 2,Differentiation Factor 2, B Cell,Differentiation Factor, B Cell,Differentiation-Inducing Protein, Myeloid,Growth Factor, Hybridoma,Growth Factor, Plasmacytoma,Hepatocyte Stimulating Factor,Interferon beta 2,Interleukin 6,Myeloid Differentiation Inducing Protein,beta-2, Interferon
D018698 Glutamic Acid A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM. Aluminum L-Glutamate,Glutamate,Potassium Glutamate,D-Glutamate,Glutamic Acid, (D)-Isomer,L-Glutamate,L-Glutamic Acid,Aluminum L Glutamate,D Glutamate,Glutamate, Potassium,L Glutamate,L Glutamic Acid,L-Glutamate, Aluminum
D018922 HL-60 Cells A promyelocytic cell line derived from a patient with ACUTE PROMYELOCYTIC LEUKEMIA. HL-60 cells lack specific markers for LYMPHOID CELLS but express surface receptors for FC FRAGMENTS and COMPLEMENT SYSTEM PROTEINS. They also exhibit phagocytic activity and responsiveness to chemotactic stimuli. (From Hay et al., American Type Culture Collection, 7th ed, pp127-8) HL60 Cells,Cell, HL60,Cells, HL60,HL 60 Cells,HL-60 Cell,HL60 Cell

Related Publications

I A Kostanyan, and R I Nurieva, and E V Navolotskaya, and M V Astapova, and S M Dranitsina, and A P Bogachuk, and V P Zav'yalov, and V M Lipkin
Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma.
May 2002, British journal of cancer,
I A Kostanyan, and R I Nurieva, and E V Navolotskaya, and M V Astapova, and S M Dranitsina, and A P Bogachuk, and V P Zav'yalov, and V M Lipkin
Arthrogenic human synovial cysts: immunohistochemical profile of interleukin-1beta, interleukin-6, tumour necrosis factor-alpha.
January 2021, Folia morphologica,
I A Kostanyan, and R I Nurieva, and E V Navolotskaya, and M V Astapova, and S M Dranitsina, and A P Bogachuk, and V P Zav'yalov, and V M Lipkin
Inhibitors of arachidonic acid metabolism potentiate tumour necrosis factor-alpha-induced apoptosis in HL-60 cells.
July 2001, European journal of pharmacology,
I A Kostanyan, and R I Nurieva, and E V Navolotskaya, and M V Astapova, and S M Dranitsina, and A P Bogachuk, and V P Zav'yalov, and V M Lipkin
Evaluation of interleukin-6, tumour necrosis factor-alpha and interleukin-1beta for early diagnosis of neonatal sepsis.
June 1999, Acta paediatrica (Oslo, Norway : 1992),
I A Kostanyan, and R I Nurieva, and E V Navolotskaya, and M V Astapova, and S M Dranitsina, and A P Bogachuk, and V P Zav'yalov, and V M Lipkin
[Mechanism of differentiating action of L-glutamic acid on HL-60 cells].
January 1998, Molekuliarnaia biologiia,
I A Kostanyan, and R I Nurieva, and E V Navolotskaya, and M V Astapova, and S M Dranitsina, and A P Bogachuk, and V P Zav'yalov, and V M Lipkin
Interleukin-1beta and tumour necrosis factor-alpha levels in periapical exudates.
February 2002, International endodontic journal,
I A Kostanyan, and R I Nurieva, and E V Navolotskaya, and M V Astapova, and S M Dranitsina, and A P Bogachuk, and V P Zav'yalov, and V M Lipkin
Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease.
February 1999, Lancet (London, England),
I A Kostanyan, and R I Nurieva, and E V Navolotskaya, and M V Astapova, and S M Dranitsina, and A P Bogachuk, and V P Zav'yalov, and V M Lipkin
[L-Glutamic acid modulates the cytotoxic effect of tumor necrosis factor in the HL-60 cell line].
January 2005, Bioorganicheskaia khimiia,
I A Kostanyan, and R I Nurieva, and E V Navolotskaya, and M V Astapova, and S M Dranitsina, and A P Bogachuk, and V P Zav'yalov, and V M Lipkin
Modulating effect of human growth hormone on tumour necrosis factor-alpha and interleukin-1beta.
June 1998, European journal of endocrinology,
I A Kostanyan, and R I Nurieva, and E V Navolotskaya, and M V Astapova, and S M Dranitsina, and A P Bogachuk, and V P Zav'yalov, and V M Lipkin
Tumour necrosis factor-alpha, interleukin-1beta and interleukin-8 induce persistent mechanical nociceptor hypersensitivity.
March 2002, Pain,
Copied contents to your clipboard!